H&R GmbH & Co. KGaA

2HRA

Equity

ISIN DE000A2E4T77 / Valor 37428602

Xetra (2026-10-15)

EUR 6.92-2.54%

H&R GmbH & Co. KGaA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

H&R GmbH & Co. KGaA, established in 1919, is a German-based company specializing in the development and manufacturing of chemical-pharmaceutical specialty products derived from crude oil. The company's product portfolio includes over 800 items such as plasticizers, white oils, paraffins, and other specialty chemicals, which are utilized across more than 100 industries. These products find applications in various sectors including the pharmaceutical and cosmetic industries, construction, plastics, and the production of industrial lubricants and process oils for the tire, rubber, paint, and coatings industries. H&R operates a global network of refineries and specialty product plants, ensuring a broad market reach. The company's shares are listed on several German stock exchanges, including the regulated market in Frankfurt (Prime Standard), as well as in Hamburg, Düsseldorf, Stuttgart, and Munich.

Summarized from source with an LLMView SourceSector: Industrials

Key financials (Q1 2025 vs Q1 2024)

Sales: €345.8m (vs €337.0m). EBITDA: €22.4m (vs €21.3m). EBIT: €7.7m (vs €6.8m). EBT: €4.7m (vs €3.6m). Consolidated net income: €2.4m (total); attributable to shareholders €1.9m (vs €1.5m). EPS (undiluted): €0.05 (vs €0.04).

Segment performance

Refining (ChemPharm Refining) led improvements: sales €217.4m and EBITDA €13.9m (+€3.4m y/y). ChemPharm Sales (international): sales €123.7m with EBITDA €9.7m (down €1.2m). Plastics (GAUDLITZ) weakened: sales €9.6m and EBITDA -€0.4m (loss versus prior-year gain).

Cash flow and liquidity

Operating cash flow was negative at -€8.1m (Q1 2024: +€11.4m), primarily driven by higher net working capital; investing cash flow -€9.7m; free cash flow -€17.7m. Cash and cash equivalents at quarter-end: €59.1m.

Balance sheet and working capital

Total assets €1,011.4m. Equity ~€466.0m with an equity ratio of 46.1%. Net working capital increased to €286.6m (+€29.7m vs 12/31/2024), driven by higher trade receivables and lower payables.

Investments and costs

Q1 capex (maintenance/modernization) ~€10.2m (slightly down y/y). Depreciation and amortization ~€14.6m. Personnel: 1,714 employees (+9).

Outlook

Management left the 2025 EBITDA guidance unchanged at €85.0–100.0m and reiterated the sales target of at least €1.3bn for 2025, noting the company is currently on track but that market/working-capital swings and geopolitical trade risks remain relevant.

Summarized from source with an LLMView Source

Key figures

40.7%1Y

43.6%3Y

-23.1%5Y

Performance

36.2%1Y

35.0%3Y

35.5%5Y

Volatility